The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program ...
It’s officially been one year since Kennedy became the nation’s health secretary. He has made numerous promises and set many ...
Facing shrinking profits and higher costs, health insurers are accelerating adoption of AI throughout their sprawling ...
Highly respected doctors on social media are endorsing questionable medical products — but they’re deepfakes, and they’re a ...
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Almost 35.5 million people were enrolled in a Medicare Advantage plan as of Feb. 1, up roughly 3% from 34.4 million at the ...
Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...
To understand what China's fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.
If IV opioids are in short supply, who gets pain relief — a teenager in agony with a crushed leg or an 80-year-old dying from cancer?
In a time of uncertainty, the public health campaign to save the CDC Injury Center offers important lessons — and hope.
What does it feel like to live in a house where your parents are getting divorced? Just ask some of the staff at Dana-Farber ...
Health secretary Robert F. Kennedy Jr. fired the starting gun in a challenge to the food industry on Sunday, announcing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results